Blockbuster Biologics Review | Issue 18

December 2022

Welcome to the latest issue of Blockbuster Biologics Review, which covers the status and developments of post-grant challenges and patent litigations implicating blockbuster biologics, and legislative proposals related to biosimilars in Q4 2022. We will continue to monitor developments in these post-grant challenges and litigations and provide you with regular updates.

Read the full report >>

BiologicsPost-Grant Challenges and Litigations
In this section, we break down post-grant challenges and Biologics Price Competition and Innovation Act (BPCIA) litigations, including the types of claims being challenged, the number filed each year, and their outcome. Notably, the current institution rate for inter partes review (IPR) challenges to patents that claim biologics—excluding IPRs that have settled or otherwise been terminated—stands at 36%.
> Download this section

BiologicsFDA—Biosimilar Approvals
This section tracks all US biosimilar approvals. The number of approved US biosimilars is 40, with the most recent approval of Idacio (adalimumab-aacf) occurring in Q4 2022.
> Download this section

BiologicsLegislative and Regulatory Updates
In this section, we highlight the Biosimilar Red Tape Elimination Act and the Consolidated Appropriations Act of 2023, the latter of which was passed by US Congress.
> Download this section

BiologicsSupporting Documents
This section provides a product-by-product breakdown of biologics-related patents that have been subject to an IPR, including the challenged claims.
> Download this section

View all past issues of Blockbuster Biologics Review >>